Wellmarker Bio’s WM-S1-030 program has been registered on the ClinicalTrials.gov website on March 16, 2021. This study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of WM-S1-030 in a total of 100 patients aged ≥18 years with advanced or metastatic solid tumors. Wellmarker Bio plans to recruit patients in multiple centers, including sites in Australia such as the Linear Clinical Center and Monash Hospital, to conduct clinical trials in two parts; a dose-escalating phase 1a(Part 1) and a dose-expansion phase 1b(Part 2).
More information can be found at ClinicalTrials.gov (Registration number: NCT04801095)
WM-S1-030 has demonstrated tumor growth inhibition in colorectal cancer model that are resistant to Erbitux (generic name: cetuximab), an anti-cancer drug commonly used as a targeted therapy in colorectal cancer. It has so far shown outstanding therapeutic efficacy in extensive preclinical studies, including Patient-Derived tumor Cell (PDC) and Patient-Derived tumor Xenograft (PDX) animal models.
More information can be found at ClinicalTrials.gov (Registration number: NCT04801095)